Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

Allowed: MYC rearrangement

High grade B-cell lymphoma with MYC and BCL2 translocation

Allowed: BCL2 rearrangement

High grade B-cell lymphoma with MYC and BCL2 translocation

Allowed: IRF4 rearrangement

Large B-cell lymphoma with IRF4 rearrangement

Allowed: ALK fusion

ALK positive large B-cell lymphoma

Must have received: systemic anti-cancer treatment

relapsed, progressive and/or refractory disease (Cheson et al. 2014) following treatment with one or two prior lines of standard therapy

Cannot have received: CAR-T cell therapy

Exception: allowed if > 4 weeks prior to registration

Any prior CAR-T or other T-cell targeting treatment (approved or investigational) ≤ 4 weeks prior to registration

Cannot have received: systemic anti-cancer treatment

Exception: allowed if > 5 half-lives or 4 weeks prior to registration, whichever is shorter; monoclonal and bispecific antibodies is acceptable

Any prior systemic anti-cancer treatment (approved or investigational) ≤ 5 half-lives or 4 weeks prior to registration, whichever is shorter

Cannot have received: golcadomide (golcadomide)

Exception: allowed if > 4 weeks prior to registration

Prior therapy with golcadomide ≤ 4 weeks prior to registration

Cannot have received: autologous stem cell transplantation

Exception: allowed if > 3 months prior to registration and all treatment-related toxicity resolved (grade ≤ 1)

Prior autologous stem cell transplantation (SCT) ≤ 3 months prior to registration. If subject had autologous SCT > 3 months prior to the start of registration, any treatment-related toxicity is unresolved (grade > 1)

Cannot have received: major surgery

Exception: allowed if > 3 weeks prior to registration

Major surgery ≤ 3 weeks prior to registration

Cannot have received: chemotherapy

Exception: allowed if > 2 weeks prior to registration

Chemotherapy ≤ 2 weeks prior to registration

Cannot have received: allogeneic stem cell transplantation

Exception: allowed if > 6 months prior to registration and all treatment-related toxicity resolved (grade ≤ 1)

prior allogeneic SCT with either standard or reduced intensity conditioning ≤ 6 months prior to registration. If subject had prior allogeneic SCT > 6 months prior to registration, any treatment-related toxicity is unresolved (grade >1)